Pacira BioSciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Pacira BioSciences, Inc.
36.39
−9.96%
vs ±9.3% implied · ×1.08
shaded = implied · ▲▼ = realized
Pacira BioSciences has 7 disclosed suppliers and 5 disclosed customers in SEC filings.
SentenceWe had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.
basisPCRX FY2025 revenue $726MMCK FY2026 revenue $403BFY mismatch
SentenceWe had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.
basisPCRX FY2025 revenue $726MCAH FY2026 revenue $254BFY mismatch
SentenceWe had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2025: McKesson Drug Company, Cardinal Health, Inc. and AmerisourceBergen Health Corporation, which accounted for 31%, 26% and 22% of our total revenues, respectively.
basisPCRX FY2025 revenue $726M
PCRX 10-Kaccession 0001628280-26-012297
SentenceIn April 2014, we entered into a Strategic Co-Production Agreement, Technical Transfer and Service Agreement and Manufacturing and Supply Agreement (the "EXPAREL Manufacturing and Supply Agreement") with Thermo Fisher Scientific Pharma Services, or Thermo Fisher, to collaborate in the manufacture of EXPAREL.
SentenceUnder the terms of the AmacaThera agreement, the Company made an upfront payment of $5.0 million to AmacaThera, recorded as R&D expense during the year ended December 31, 2025, with the potential for future development- and sales-based milestone payments and a tiered royalty on future net product sales.
PCRX 10-Kaccession 0001628280-26-012297
SentenceIn January 2025, we and Jubilant Hollisterstier, LLC, or Jubilant, entered into a Manufacture and Supply Agreement (the "Jubilant Agreement") to collaborate in the manufacture of the diluent for ZILRETTA at Jubilant's Spokane, Washington facility.
PCRX 10-Kaccession 0001628280-26-012297
SentencePursuant to an agreement with the Research Development Foundation, or RDF, we were required to pay RDF a low single-digit royalty on the collection of revenues from certain products for as long as certain patents assigned to us under the agreement remain valid.
PCRX 10-Kaccession 0001628280-26-012297
SentenceWe also had in-licensed intellectual property, owned by the Southwest Research Institute, or SwRI, which gave us exclusive rights to SwRI patents covering our proprietary microsphere manufacturing technology used in the production of ZILRETTA.
PCRX 10-Kaccession 0001628280-26-012297
SentenceAratana pays us a tiered double-digit royalty on certain net sales made in the U.S., and we are eligible to receive up to $40.0 million upon the achievement of commercial milestones.
PCRX 10-Kaccession 0001628280-26-012297
SentenceIn addition, we will supply EXPAREL product and LG Chem will be responsible for securing regulatory approvals in the licensed territories.
PCRX 10-Kaccession 0001628280-26-012297
Expected move
No implied move.